Cytokinetics Names Robert E. Landry to Board of Directors

Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential Commercialization SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of Robert E. Landry to its Board of Directors. Mr. Landry brings over three decades of financial and operational expertise in the pharmaceutical industry, most recently having served as the Chief Financial Officer at Regeneron Pharmaceuticals Inc. for 11 years. “We are pleased to have Bob join our Board as we approach a key shareholder value inflection point for the company and prepare for the potential approval and launch of our first medicine,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “His extensive career in finance and expertise spanning financial engineering, capital allocation and efficiencies, tax strategy and treasury management will be important as we advance toward commercialization. His leadership at Regeneron, guiding the company’s global scaling, while maintaining disciplined spending and a steadfast commitment to innovation in research and development, aligns with our vision at Cytokinetics of becoming a fully integrated company achieving sustainable growth.” In his role as Chief Financial Officer at Regeneron, Mr. Landry was responsible for all financial operations as well as investor relations, information technology, competitive intelligence and global non-manufacturing facilities, helping guide the company as it grew substantially in market capitalization and workforce over more than a decade. During his tenure he oversaw two public acquisitions, Checkmate Pharmaceuticals and Decibel Therapeutics, and established affiliates around the world. Prior to joining Regeneron, Mr. Landry spent 25 years at Wyeth and Pfizer Inc., where he held numerous corporate and operational roles including Corporate Treasurer, Senior Vice President of Finance, Director of Pharmaceutical Marketing and Sales, and Chief Financial Officer of Wyeth Australia and New Zealand. Mr. Landry started his career at Coopers & Lybrand, now PricewaterhouseCoopers LLP. He was a Certified Public Accountant in New York and received a Bachelor of Business Administration from the University of Notre Dame. About Cytokinetics Cytokinetics is a late-stage, muscle biology specialty biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, Cytokinetics is intent on meaningfully improving the lives of patients through global access to innovative medicines. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a potential next-in-class cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function. For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube. Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. Contact:Cytokinetics Diane WeiserSenior Vice President, Corporate Affairs(415) 290-7757

Cytokinetics Names Robert E. Landry to Board of Directors

FAQ

Why Bullish?

How important is it?

Why Short Term?

Related Companies

Related News